
Neuro-Oncology + Behavioral Neurology @mayoclinic | @mayoneurores + @WakeForest + @floridastate alum | Science. Art. Flavor. | Views are my own
Minnesota, USA
Joined October 2011
- Tweets3.1K
- Following2.7K
- Followers852
- Likes5.1K
In three patients with refractory epilepsy, hippocampal chemogenetic therapy plus low-dose clozapine was associated with a mean seizure-frequency reduction of 92.6%. Adverse events were grade 1 or 2. Full study results: nej.md/4Agtyhz

ALT Bar chart showing the frequency of monthly seizures for Patients 1, 2, and 3 before and after chemogenetic neuromodulation treatment. Orange bars indicate the number of seizures before treatment: Patient 1 has 4.5, Patient 2 has 4.0, and Patient 3 has 4.5. Purple bars indicate the number of seizures after treatment: Patient 1 has 0.5, Patient 2 has 0, and Patient 3 has 0.5. The vertical axis represents the number of seizures per month.
Bryan Neth, MD, PhD retweeted
Click anywhere on the brain and see that region's projections.
Fibers are diffusion tractography (dMRI) from Human Connectome Project
amyleesterling.github.io/hum…
Bryan Neth, MD, PhD retweeted
Check out our phase 2 trial using Memory avoidant (MA)WBRT, improved cognitive preservation compare to historical HA-WBRT. Out now in Neuro Onc advances
academic.oup.com/noa/advance…
Bryan Neth, MD, PhD retweeted
🚨🚨Randomized Trial: How does Hypofraction compare to Standard of Care Stupp regimen for GBM?
POORLY, according to the Gold trial with worse OS and increased radiation necrosis thegreenjournal.com/article/…
Bryan Neth, MD, PhD retweeted
The recommendation to perform serum SPEP with immunofixation in every case of distal symmetric polyneuropathy has caused unnecessary harm to patients. This advice has been repeated so often that many regard it as an absolute truth. However, Dr. Go and colleagues from @MayoClinic Hematology demonstrate the very low clinical utility of monoclonal gammopathy testing in patients with peripheral neuropathy. link.springer.com/article/10…
Bryan Neth, MD, PhD retweeted
🚨 Out today in Cell! @CellCellPress
Path2Space: #AI that predicts spatial transcriptomics (ST) from H&E pathology, enabling spatial biomarker discovery in #BreastCancer at scale.
📄 doi.org/10.1016/j.cell.2026.…
🧵1/8
Bryan Neth, MD, PhD retweeted
Grateful for our team effort featured by Mayo Clinic News Network—developing a blood test to detect germ cell tumors missed by standard markers.
newsnetwork.mayoclinic.org/d…
Bryan Neth, MD, PhD retweeted
Our paper in @Nature today 🥳 We tracked 6,438 mice from puberty to death and mapped the genetics of *when* you die, not just whether a gene associates with lifespan.
nature.com/articles/s41586-0…
59 loci. Two decades of data. Thread 👇
#Longevity #Aging #Genetics #Healthspan
Bryan Neth, MD, PhD retweeted
Honored to have a @NatRevClinOncol publication on the work we & colleagues have done on #meningiomas
Research & discoveries improving #care #clinicaltrials
@ICOMeningioma @MeningiomaBot
RT 🙏🏻 @mayoclinic @MayoRadOnc @MayoCancerCare @MayoClinicNeuro
Thanking all #collaborators
New online! Multidisciplinary management of meningiomas in the era of precision oncology dlvr.it/TS17pK
Bryan Neth, MD, PhD retweeted
Why do only some cancer patients develop #paraneoplastic neurological syndromes (PNS)? 🧠
This review explores the immune mechanisms behind PNS and how tumor genetics & immune tolerance shape risk. Kudos to @AKunchok. Open access link: journals.lww.com/co-neurolog…
Bryan Neth, MD, PhD retweeted
Should we treat higher SRS doses for brainstem mets (than the typical lower doses used)?
Tumor control probability MODELING:
1 Yr 90%LC 18.9 Gy/1, 25.7/3, 28.6/5
2 Yr 90%LC 20.5 Gy/1, 28.2/3, 31.5/5
sciencedirect.com/science/ar…
Bryan Neth, MD, PhD retweeted
Editorial CATNON IDHmt Grade 3 Astrocytoma
· NO benefit concurrent temozolomide
· Sig benefit w/adjuvant TMZ
· MGMT NOT prognostic
· Poor prog CDKN2A/B homo deletion, PDGFRA amp, methy profile
academic.oup.com/neuro-oncol…
Bryan Neth, MD, PhD retweeted
What is the long term control Sporadic Vestibular Schwannoma after radiosurgery?
LC 5, 10, & 15 years 96%, 92%, & 91%
13% pseudoprogression median time 0.5 yrs (only 4% >5yr after SRS) doi.org/10.3171/2025.8.JNS25…
For decades, researchers have noted that cancer and Alzheimer’s disease are rarely found in the same person
go.nature.com/4qIHwo2
Bryan Neth, MD, PhD retweeted
Gonzalez-Aponte et al. reported circadian rhythms in MGMT promoter methylation and protein levels in GBM, with peaks at midday and CT4, respectively, predicting time-of-day differences in temozolomide efficacy. #JNO
Read more:link.springer.com/article/10…
Bryan Neth, MD, PhD retweeted
Also this came out today!
newsnetwork.mayoclinic.org/d…
Bryan Neth, MD, PhD retweeted
Cognitive recovery after radiation brain mets meta-analysis
· 1/3 cognitive recovery @6mo after initial decline
· Recovery more likely if SRS or HA-WBRT compared to WBRT
academic.oup.com/jnci/articl…
Bryan Neth, MD, PhD retweeted
A decade after our world-first BBB opening for #GBM, our newest trial shows FUS is safe, well-tolerated, with signals of benefit.
A major milestone for a devastating illness.
Grateful to @INSIGHTEC, @FUSFoundation, our donors, and brave patients.
sciencedirect.com/science/ar…






















